Into clinical practice:

Pneumonia

22 January 2021

Conference webinar

A VIRTUAL CONVERENCE HELD ON 22 JANUARY 2021.

This conference webinar was held on 22 January 2021 and explores the current challenges and treatment opportunities for Pneumonia.

We hope you enjoy this conference webinar.

Programme

0930
Opening remarks
Professor Philip Howard OBE, Consultant Antimicrobial Pharmacist, Leeds Teaching Hospitals and University of Leeds & BSAC President - View Bio

SESSION ONE: Understanding Pneumonia
Chair: Professor Philip Howard OBE, Consultant Antimicrobial Pharmacist, Leeds Teaching Hospitals and University of Leeds & BSAC President
0935
Definitions, classifications and epidemiology of pneumonia
Professor James Chalmers, Dundee - View Bio
0955
Understanding the burden - adults
Dr Vanya Gant, UCLH
1015
Understanding the burden - paediatrics
Dr Paddy McMaster - View Bio
1035
Q&A
All speakers

SESSION TWO: Pneumonia in different settings & following the guidance
Chair: Professor Elizabeth Sapey, Professor in Acute and Respiratory Medicine, University of Birmingham
1110
Hospital acquired pneumonia- treatment options and guidelines
Professor Matteo Bassetti, Infectious Diseases, Department of Health Science, University of Genoa - View Bio
1130
Community acquired pneumonia
Marisa Lanzman, Senior Pharmacist – Microbiology & ITU, Royal Free London NHS Foundation Trust - View Bio
1150
Nice guidelines and the impact of pneumonia in the community
Dr Tessa Lewis, GP, Medical Adviser & Chair NICE Managing Common Infections Committee, NHS - View Bio
1210
CQUINs and other official guidance for pneumonia 
Professor Philip Howard OBE, Consultant Antimicrobial Pharmacist, Leeds Teaching Hospitals and University of Leeds & BSAC President - View Bio
1230
Q&A
All speakers

SESSION THREE: Session supported by Pfizer
1325
Treating HAP/VAP in critically ill patients
Professor Antoni Torres, Professor of Medicine and Head of Respiratory Intensive Care Unit, Hospital Clinic of Barcelona, University of Barcelona

SESSION FOUR: Session supported by Shionogi
1350
Cefiderocol and the pneumonia patient pathway

SESSION FIVE: COVID-19: Lessons learnt
Chair: Dr David Jenkins, Lead Infection Prevention Clinician, University Hospital Leicester & BSAC Vice-President
1415
Point of Care Molecular diagnostics in the diagnosis of bacterial co-infection in COVID19 patients
Dr Joshua Moorhouse, Speciality Registrar in Intensive Care Medicine and Anaesthetics, John Radcliffe Hospital Oxford - View Bio
1435
The anti-viral and anti-cytokine effects of baricitinib: stitching together a dual mechanism
Professor Justin Stebbing, Professor of Cancer Medicine and Oncology, NIHR Research Translational Professor, Imperial College London - View Bio
1455
Q&A
All speakers

SESSION SIX: The future - improving the management of pneumonia
Chair: Dr Christopher Longshaw, Infectious Diseases, Shionogi B.V., London, UK
1525
Pneumococcal vaccines and Pneumonia
Dr Rajeka Lazarus, Consultant in Infection, University Hospital Bristol & Weston - View Bio
1545
The INHALE Study: what have we learnt about the molecular diagnostics of HAP/VAP in critical care?
Dr Vicky Enne, Senior Research Fellow, UCL - View Bio
1605
Q&A
All speakers

SESSION SEVEN: Session supported by Pfizer
1620
Invasive aspergillosis management in ICU patients with respiratory infections
Dr Silke Schelenz, Consultant Microbiologist, King’s College Hospital

1645
Closing remarks
Professor Philip Howard OBE, Consultant Antimicrobial Pharmacist, Leeds Teaching Hospitals and University of Leeds & BSAC President - View Bio

Posters & abstracts

Having trouble finding what you're after?

Top